|
Real-time Estimate
Cboe BZX
11:45:00 2026-06-10 am EDT
|
5-day change
|
1st Jan Change
|
|
296.74 USD
|
-0.32%
|
 |
+1.03%
|
-25.66%
|
|
May. 27 |
Alnylam Pharmaceuticals, Inc. Elects Benjamin F. Cravatt as Class III Director and Member of Board?s Science and Technology Committee, Effective as of June 1, 2026
|
CI
| |
Mar. 05 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $2,227,698, According to a Recent SEC Filing
|
MT
| |
Feb. 18 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,284,980, According to a Recent SEC Filing
|
MT
| |
Feb. 18 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $607,448, According to a Recent SEC Filing
|
MT
| |
Feb. 18 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $2,157,542, According to a Recent SEC Filing
|
MT
| |
Feb. 18 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $695,201, According to a Recent SEC Filing
|
MT
| |
Jan. 14 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,395,992, According to a Recent SEC Filing
|
MT
| |
Jan. 14 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $547,927, According to a Recent SEC Filing
|
MT
| |
Jan. 14 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,008,766, According to a Recent SEC Filing
|
MT
| |
Jan. 14 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,475,157, According to a Recent SEC Filing
|
MT
| |
Jan. 14 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $547,929, According to a Recent SEC Filing
|
MT
| |
Jan. 13 |
Alnylam Pharmaceuticals CEO on Development Goals, Profitability
|
MT
| |
Dec. 03 |
Alnylam Pharmaceuticals Announces Changes to Board of Directors
|
CI
| |
Dec. 03 |
Alnylam Pharmaceuticals announces changes to board of directors
|
RE
| |
25-10-03 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $2,692,062, According to a Recent SEC Filing
|
MT
| |
25-10-03 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,103,451, According to a Recent SEC Filing
|
MT
| |
25-10-03 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $635,126, According to a Recent SEC Filing
|
MT
| |
25-10-03 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,034,085, According to a Recent SEC Filing
|
MT
| |
25-09-02 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,557,649, According to a Recent SEC Filing
|
MT
| |
25-08-19 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $632,759, According to a Recent SEC Filing
|
MT
| |
25-08-19 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,163,346, According to a Recent SEC Filing
|
MT
| |
25-08-19 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,030,727, According to a Recent SEC Filing
|
MT
| |
25-08-19 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $632,759, According to a Recent SEC Filing
|
MT
| |
25-08-19 |
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,299,746, According to a Recent SEC Filing
|
MT
| |
25-06-18 |
Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer
|
CI
|
No results match your criteria Select your edition All financial news and data tailored to specific country editions | 
